\begin{table}\footnotesize
\begin{center}
  \begin{tabular}{|l|c|c|c|}
  \hline
  KEGG Pathway & ENV HHP/HHE & NEF HHP/HHE & TAT HHP/HHE\\
  \hline
AML & 1.97E-05/2.68E-05 & 2.07E-05/8.55E-05 & 2.66E-08/3.08E-04 \\
Adherens junction & 2.15E-09/NA & 8.21E-11/NA & 6.74E-06/NA \\
Apoptosis & 4.58E-04/1.43E-13 & 5.18E-04/6.54E-04 & 3.91E-03/3.88E-13 \\
B cell receptor signaling & 4.86E-06/8.73E-10 & 2.88E-04/2.90E-04 & 1.25E-09/5.57E-06 \\
Cell cycle & NA/NA & NA/NA & 2.88E-04/1.90E-01 \\
CML & 7.21E-05/2.23E-05 & 1.17E-06/2.46E-05 & 1.01E-09/7.53E-07 \\
Colorectal cancer & 1.07E-05/3.18E-04 & 4.68E-08/3.31E-03 & 4.50E-04/1.42E-03 \\
Endometrial cancer & 6.03E-04/1.62E-02 & 1.66E-04/2.10E-03 & 5.03E-07/3.83E-04 \\
H. pylori infection & 2.29E-04/3.84E-06 & 2.07E-06/2.83E-05 & NA/NA \\
ErbB signaling & 2.27E-10/5.70E-04 & 1.70E-12/9.22E-04 & 1.53E-12/1.66E-05 \\
Fc epsilon RI signaling & 8.43E-04/6.23E-21 & 2.14E-05/2.20E-07 & 9.62E-05/1.52E-04 \\
Focal adhesion & 2.82E-06/2.30E-03 & 2.31E-07/6.90E-02 & 5.28E-08/3.36E-09 \\
Gap junction & 1.90E-04/1.26E-04 & NA/NA & 1.12E-04/7.18E-10 \\
Glioma & 1.50E-04/1.24E-05 & 4.99E-06/6.02E-03 & 1.56E-07/6.79E-11 \\
Insulin signaling & 1.53E-07/8.84E-02 & 1.73E-04/3.50E-01 & 2.91E-07/7.35E-02 \\
Jak-STAT signaling & 4.08E-08/2.15E-04 & 4.09E-09/1.28E-01 & 2.32E-17/4.91E-03 \\
Leukocyte migration & 1.94E-07/2.21E-08 & 1.17E-08/6.36E-01 & 3.28E-05/1.45E-01 \\
Long-term potentiation & 6.79E-05/2.20E-02 & NA/NA & 9.04E-03/2.38E-10 \\
MAPK signaling & 5.19E-08/6.32E-04 & 1.58E-09/3.27E-03 & 1.18E-03/5.15E-01 \\
NK cell cytotoxicity & NA/NA & NA/NA & 9.50E-06/5.31E-15 \\
Non-small cell lung cancer & 4.28E-05/1.25E-04 & 1.26E-05/1.67E-03 & 7.55E-06/1.45E-06 \\
Pancreatic cancer & 1.26E-04/5.54E-07 & 1.10E-05/2.50E-06 & 1.03E-05/8.15E-08 \\
E. coli infection & 3.77E-03/1.00E+00 & 2.94E-03/NA & 9.74E-03/3.25E-01 \\
PtdIns signaling & 1.36E-03/1.72E-04 & 2.37E-03/NA & 2.19E-05/9.74E-06 \\
Prostate cancer & 1.90E-04/1.26E-04 & 6.26E-06/6.56E-05 & 5.46E-09/1.11E-07 \\
Regulation of cytoskeleton & 4.30E-03/6.02E-01 & 1.73E-03/8.79E-01 & 2.66E-03/7.65E-01 \\
Small cell lung cancer & 1.94E-03/3.71E-10 & 8.42E-05/4.25E-02 & 1.12E-04/4.09E-14 \\
T cell receptor signaling & NA/NA & NA/NA & 1.56E-06/1.35E-11 \\
Tight junction & 1.24E-03/1.00E+00 & 5.29E-04/NA & NA/NA \\
Toll-like receptor signaling & 5.16E-03/2.04E-14 & 5.37E-05/2.04E-14 & NA/NA \\
Type II diabetes mellitus & NA/NA & NA/NA & 3.47E-03/5.95E-01 \\
VEGF signaling & 3.23E-03/4.89E-15 & 6.79E-03/8.82E-03 & 1.88E-05/4.07E-12 \\
\hline
  \end{tabular}
\end{center}
\caption[KEGG pathway enrichment for predicted and experimentally
  verified HIV targeted human proteins]{\small Here we show KEGG
  pathways enriched (p-value $<$ 0.01, see Methods) with human proteins
  from our predicted virus-host interactions (HHP) for HIV ENV, NEF,
  and TAT. Enrichment for host proteins involved in NCBI's verified
  virus-host interactions (HHE) is also
  indicated. \label{tbl:medGen1:KEGG}}
\end{table}
